Survodutide
GLP-1 / Glucagon dual agonist
A dual GLP-1/glucagon agonist — and notable MASH data.
Half-life
~ several days (once-weekly)
Mol. weight
~ 4 kDa (modified dual agonist)
Sequence
GLP-1 / glucagon-based dual agonist
Discussions
0 threads
Overview
Survodutide (BI 456906) is an investigational once-weekly dual agonist of GLP-1 and glucagon receptors in development for obesity and for metabolic dysfunction-associated steatohepatitis (MASH). The glucagon component is of particular interest for its potential effects on hepatic fat, and early trials reported strong MASH resolution signals.
Mechanism of action
Survodutide activates GLP-1 and glucagon receptors. The GLP-1 component drives appetite suppression, slowed gastric emptying, and insulinotropic effects; the glucagon component is hypothesized to increase energy expenditure and directly affect hepatic lipid metabolism — the rationale behind its MASH (NASH) development program.
Researched benefits
- Dual GLP-1 + glucagon agonism
- Studied for obesity and for MASH/NASH (hepatic fat)
- Glucagon component may target liver fat directly
- Once-weekly dosing (investigational)
Considerations
- Investigational; not approved
- Glucagon agonism introduces hepatic and metabolic safety questions under study
- GI side effects expected and dose-dependent
- Requires medical supervision
Key Academic Literature & Studies
Search more in PubMedPeer-reviewed citations and clinical trials evaluating Survodutide in scientific literature.
Query PubMed for recent peer-reviewed preclinical and clinical publications on Survodutide:
View Survodutide index on PubMed (NCBI)